ABL Bio (XKRX:298380) Debt-to-Equity : 0.68 (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is ABL Bio Debt-to-Equity?

ABL Bio's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩531 Mil. ABL Bio's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩43,071 Mil. ABL Bio's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ₩63,808 Mil. ABL Bio's debt to equity for the quarter that ended in Mar. 2024 was 0.68.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for ABL Bio's Debt-to-Equity or its related term are showing as below:

XKRX:298380' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.02 Max: 0.68
Current: 0.68

During the past 8 years, the highest Debt-to-Equity Ratio of ABL Bio was 0.68. The lowest was 0.01. And the median was 0.02.

XKRX:298380's Debt-to-Equity is ranked worse than
80.37% of 1070 companies
in the Biotechnology industry
Industry Median: 0.14 vs XKRX:298380: 0.68

ABL Bio Debt-to-Equity Historical Data

The historical data trend for ABL Bio's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ABL Bio Debt-to-Equity Chart

ABL Bio Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.01

0.02

0.01

0.60

0.59

ABL Bio Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.43	0.47	0.48	0.59	0.68

Competitive Comparison of ABL Bio's Debt-to-Equity

For the Biotechnology subindustry, ABL Bio's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ABL Bio's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ABL Bio's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where ABL Bio's Debt-to-Equity falls into.

ABL Bio Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

ABL Bio's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(784.473	+	43153.525)	/	74079.11
	=	0.59

ABL Bio's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(531.253	+	43070.554)	/	63807.832
	=	0.68

ABL Bio (XKRX:298380) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

ABL Bio Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of ABL Bio's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

ABL Bio (XKRX:298380) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ABL Bio Inc (XKRX:298380) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

2nd Floor, 16 Daewangpangyo-Ro 712, Beon-Gil, Bundang-Gu, Gyeonggi-do, Seongnam-si, KOR, 13488

Website

https://www.ablbio.com

ABL Bio Inc is a Korean biotech research company. The company is engaged in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline products include ABL001 an Bispecific Antibody, ABL201-205 an Antibody Drug Conjugate, T cell engager, Dual Immune Cell Targeting BsAb an Immuno-Oncology, ABL301 an BBB-Penetrating Bispecific Antibody.

ABL Bio (XKRX:298380) Headlines

No Headlines